Related to Lilly Buys Avid for $300M for Phase III Amyloid Plaque Imaging Agent

• Amylin and Lilly’s Byetta Sanctioned as Monotherapy for Type 2 Diabetes
  
• Scientists Find Marketed Alzheimer’s Drug Has Potential Against Huntington’s
  
• Good and Bad News at Idera
  
• ExonHit Launches Alzheimer Diagnostic for Research Use
  
• Scientists Claim Short Amyloid Fibers Are More Toxic than Their Longer Counterparts
  
• FDA Approves First Generic Version of Pfizer and Eisai’s Alzheimer Drug
  
• Researchers Identify Proteins that Contribute to Memory Loss and Alzheimer Disease
  
• Studies Find Link between Alzheimer Disease, Down Syndrome, and Atherosclerosis
  
• Lilly Negotiates Option to License Alizé’s Preclinical Type 2 Diabetes Program
  
• Geron to Study Its hESC Product in Alzheimer Disease with University of California
  
• Scientists Associate Modified Form of Protein with Three Neurodegenerative Diseases
  
• ExonHit Joins EU’s PharmaCog Alzheimer Disease Consortium
  
• Lilly, Merck & Co., and Pfizer Establish Asian Cancer Research Group Focused on Lung and Gastric Cancers
  
• Potential Early Diagnostic Biomarker for Alzheimer Disease in Healthy Adults Identified
  
• Scientists Identify Sea Squirt as Model for Alzheimer Disease Research and Drug Testing
  
• Transition Therapeutics and Lilly Expand Diabetes Partnership through Licensing of the Latter’s Preclinical Candidates
  
• Pfizer and Medivation’s Alzheimer Drug Fails in First Phase III Trial
  
• FDA Stalls Approval of Amylin, Lilly, and Alkermes’ Type 2 Diabetes Therapy
  
• Approved Immunosuppressant Found to Be Effective in Mouse Model of Alzheimer Disease
  
• Investigators Find Gene Linked to Risk of Late-Onset Alzheimer Disease